283 related articles for article (PubMed ID: 36555262)
1. Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.
Lundstrom K
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555262
[TBL] [Abstract][Full Text] [Related]
2. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
3. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P; Dispenzieri A; Galanis E
Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
[TBL] [Abstract][Full Text] [Related]
4. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
[TBL] [Abstract][Full Text] [Related]
10. Potential and clinical translation of oncolytic measles viruses.
Robinson S; Galanis E
Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
[TBL] [Abstract][Full Text] [Related]
11. Alphaviruses in cancer immunotherapy.
Lundstrom K
Int Rev Cell Mol Biol; 2023; 379():143-168. PubMed ID: 37541722
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
16. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
18. Replicon RNA Viral Vectors as Vaccines.
Lundstrom K
Vaccines (Basel); 2016 Nov; 4(4):. PubMed ID: 27827980
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
20. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
